BeiGene presents new analyses for BRUKINSA

BeiGene announced the presentation of new analyses for BRUKINSA at the American Society of Clinical Oncology Annual Meeting in Chicago, May 31 – June 4, 2024. The presentations highlight analyses of the efficacy and safety of BRUKINSA compared to other Bruton’s tyrosine kinase inhibitors used to treat chronic lymphocytic leukemia and small lymphocytic lymphoma. “At this year’s ASCO, multiple presentations continue to add to our extensive body of evidence demonstrating BRUKINSA’s uniquely differentiated clinical profile,” Mehrdad Mobasher, M.D., M.P.H., Chief Medical Officer, Hematology at BeiGene. “These new analyses, which highlight improved PFS and response rates and a low usage of antihypertensive medicines, provide valuable insights for oncologists to consider when making treatment decisions for their patients with CLL and SLL.” A network meta-analysis evaluated the relative efficacy of available treatments for patients with high-risk relapsed/refractory CLL using data from three randomized controlled clinical trials: ALPINE, ELEVATE-RR and ASCEND. The analysis found a statistically significant improvement in PFS for BRUKINSA over acalabrutinib in high-risk patients and a trend toward improvement in overall survival, overall response and complete response. BRUKINSA led to statistically significant improvements in PFS, as well as a trend toward improvement in OS, vs. ibrutinib and bendamustine + rituximab/idelalisib + rituximab.